title: Seattle Genetics rare cancer drug sails through accelerated approval.
authors: Laura
authors: L
authors: DeFrancesco
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D000079963:Brentuximab Vedotin; D002986:Clinical Trials as Topic; D017277:Drug Approval; D004345:Drug Industry; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy*; D035583:Rare Diseases / Q000188:drug therapy*; D012008:Recurrence; D014481:United States; D014486:United States Food and Drug Administration; D014861:Washington
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018796:Immunoconjugates; D000068258:Bevacizumab; D000079963:Brentuximab Vedotin